Takeyuki Nagashima

Discovery of Novel Forkhead Box O1 Inhibitors for Treating Type 2 Diabetes: Improvement of Fasting Glycemia in Diabetic db/db Mice

Takeyuki Nagashima, Nobuharu Shigematsu, Riyo Maruki et al. · Molecular Pharmacology · 2010 · 277 citations

Life Sciences, Endocrinology, Pharmacology +13

Efficient delivery of siRNA using dendritic poly(l-lysine) for loss-of-function analysis

Yusuke Inoue, Ryosuke Kurihara, Akiko Tsuchida et al. · Journal of Controlled Release · 2007 · 111 citations

Pharmacy, Molecular Biology, Pharmaceutics +15

ASP3082, a First-in-class novel KRAS G12D degrader, exhibits remarkable anti-tumor activity in KRAS G12D mutated cancer models

Takeyuki Nagashima, K. Inamura, Y. Nishizono et al. · European Journal of Cancer · 2022 · 55 citations · Full text

Medicine, Molecular Biology, Oncology +11

Diclofenac, a non-steroidal anti-inflammatory drug, suppresses apoptosis induced by endoplasmic reticulum stresses by inhibiting caspase signaling

Takao Yamazaki, Masakazu Muramoto, Tomoya Oe et al. · Neuropharmacology · 2006 · 53 citations

Life Sciences, Cell Biology, Pharmacology +14

Effects of the novel Foxo1 inhibitor AS1708727 on plasma glucose and triglyceride levels in diabetic db/db mice

Hirotsugu Tanaka, Takeyuki Nagashima, Akiyoshi Shimaya et al. · European Journal of Pharmacology · 2010 · 37 citations

Medicine, Biochemistry, Endocrinology +17